Experienced in Hepatitis A

Xianling N. Liu

139 Middle Renmin Road, 
Changsha, CN 
Experienced in Hepatitis A
139 Middle Renmin Road, 
Changsha, CN 
OverviewLocationsClinical Research

Overview

Xianling Liu practices in Changsha, China. Liu is rated as an Experienced expert by MediFind in the treatment of Hepatitis A. Their top areas of expertise are Nasopharyngeal Carcinoma, Lung Cancer, Lung Adenocarcinoma, Non-Small Cell Lung Cancer (NSCLC), and Tissue Biopsy.

Their clinical research consists of co-authoring 79 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Hepatitis A.

Locations

139 Middle Renmin Road, Changsha, 410011, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multicenter, Open-label, Exploratory Phase II Clinical Study to Evaluate the Safety and Tolerability and Preliminary Efficacy of TJ107 Combine With Pembrolizumab Injection in Patients With Locally Advanced or Metastatic Solid Tumors
A Multicenter, Open-label, Exploratory Phase II Clinical Study to Evaluate the Safety and Tolerability and Preliminary Efficacy of TJ107 Combine With Pembrolizumab Injection in Patients With Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: April 15, 2024
Intervention Type: Biological
Study Drugs: TJ107, Pembrolizumab
Study Phase: Phase 2
A Multi-center, Single Arm , Phase II Study of Atezolizumab Combined With Concurrent Chemoradiotherapy and Maintenance Therapy With Atezolizumab in Untreated Participants With Extensive-stage Small Cell Lung Cancer
A Multi-center, Single Arm , Phase II Study of Atezolizumab Combined With Concurrent Chemoradiotherapy and Maintenance Therapy With Atezolizumab in Untreated Participants With Extensive-stage Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: June 14, 2022
Intervention Type: Procedure
Study Phase: Phase 2
View 1 Less Clinical Trial

79 Total Publications

Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer.
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer.
Journal: The New England journal of medicine
Published: October 22, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Liu's expertise for a condition
ConditionClose
      View All 12 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile